公开(公告)号：WO1995016920A1

公开(公告)日：1995-06-22

申请号：PCT/US1994014455

申请日：1994-12-16

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  MARCH, Steven, C. ,  JENG, Tzyy-Wen

IPC: G01N33/74

CPC classification number: G01N33/743 ,  G06F19/00 ,  G16H40/63

Abstract: Provided is a highly reliable method to predict the beginning and/or ending of the fertile period for a female for each menstrual cycle. The methods and means provided advantageously address the day-to-day, cycle-to-cycle, and women-to-women variability in fertility hormone levels by analyzing the measurements of serial hormone concentrations in the midst of daily hormonal variations to determine when an actual and significant increase in the concentration of the monitored hormone has begun. Thus the present disclosure is directed to a method that combines existing hormone assay methods with calculation procedures to optimize the predictive values of daily hormonal changes. In this way a reliable and useful prediction of the fertile period is achieved with the concomitant assurance that the beginning and/or end of the fertile period has been reached so that such declarations are sufficient to provide both fertility enhancement and contraceptive utility.

Abstract translation: 提供了一种高度可靠的方法来预测每个月经周期中女性的肥沃期的开始和/或结束。 提供的方法和手段有利地通过分析日常激素变异中的连续激素浓度的测量来确定生育激素水平的日常，周期与周期以及妇女与女性的变异性，以确定何时 监测的激素的浓度的实际和显着增加已经开始。 因此，本公开涉及将现有激素测定方法与计算程序组合以优化每日激素变化的预测值的方法。 以这种方式，可以有效地预测肥沃期，同时确保已经达到肥沃期的开始和/或结束，以便这种声明足以提供生育能力和避孕效用。

公开(公告)号：WO1994020636A1

公开(公告)日：1994-09-15

申请号：PCT/US1994002539

申请日：1994-03-09

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  BRATE, Elaine, M. ,  BRENNAN, Catherine, A. ,  BRIDON, Dominique, P. ,  JAFFE, Keeve, D. ,  KRAFFT, Grant, A. ,  MANDECKI, Wlodzimierz ,  MARCH, Steven, C. ,  RUSSELL, John, C. ,  YUE, Vincent, T.

IPC: C12Q01/00

CPC classification number: C07K14/59 ,  C07K2319/40 ,  C12N9/16 ,  C12Q1/42

Abstract: This invention relates to genetically engineered enzymes, their ligand conjugates, their manufacture, and their use in qualitative or quantitative assays. A hybrid enzyme, such as an AP-epitope, has a foreign amino acid moiety (an epitope) inserted near the active site of the starting AP enzyme. The foreign amino acid moiety binds with an analyte, and, as a consequence of this binding, the enzymatic activity of the hybrid enzyme, AP-epitope, is modified. The changes in the enzymatic activity are dependent upon the presence, or the amount, of the analyte. In another embodiment, the hybrid enzyme consists of a cysteine introduced near the active site of an AP to give a hybrid enzyme. The cysteine on the hybrid enzyme serves as a point of conjugation of a ligand, such as theophylline, ferritin, thyroxine, or digoxigenin, to form the hybrid enzyme-ligand conjugate. The ligand binds with an antibody, an analyte or a binding molecule to an analyte and as a result of this binding, the enzymatic activity of the hybrid enzyme-ligand conjugate is modified or modulated.

Abstract translation: 本发明涉及基因工程改造的酶，其配体缀合物，其制备及其在定性或定量测定中的用途。 诸如AP-表位的杂交酶在起始AP酶的活性位点附近插入外源氨基酸部分（表位）。 外来氨基酸部分与分析物结合，并且作为该结合的结果，修饰了杂合酶AP-表位的酶活性。 酶活性的变化取决于分析物的存在或数量。 在另一个实施方案中，杂交酶由在AP的活性位点附近引入的半胱氨酸组成以产生杂交酶。 杂交酶上的半胱氨酸用作配体如茶碱，铁蛋白，甲状腺素或地高辛的缀合点，以形成杂交酶 - 配体缀合物。 配体与分析物结合抗体，分析物或结合分子，作为该结合的结果，修饰或调节杂交酶 - 配体结合物的酶活性。

公开(公告)号：EP0688364A1

公开(公告)日：1995-12-27

申请号：EP94913281.0

申请日：1994-03-09

Applicant: ABBOTT LABORATORIES

Inventor： BRATE, Elaine, M. ,  BRENNAN, Catherine, A. ,  BRIDON, Dominique, P. ,  JAFFE, Keeve, D. ,  KRAFFT, Grant, A. ,  MANDECKI, Wlodzimierz ,  MARCH, Steven, C. ,  RUSSELL, John, C. ,  YUE, Vincent, T.

IPC: G01N33 ,  C07K14 ,  C12N9 ,  C12N15 ,  C12Q1 ,  C12R1

CPC classification number: C07K14/59 ,  C07K2319/40 ,  C12N9/16 ,  C12Q1/42

Abstract: This invention relates to genetically engineered enzymes, their ligand conjugates, their manufacture, and their use in qualitative or quantitative assays. A hybrid enzyme, such as an AP-epitope, has a foreign amino acid moiety (an epitope) inserted near the active site of the starting AP enzyme. The foreign amino acid moiety binds with an analyte, and, as a consequence of this binding, the enzymatic activity of the hybrid enzyme, AP-epitope, is modified. The changes in the enzymatic activity are dependent upon the presence, or the amount, of the analyte. In another embodiment, the hybrid enzyme consists of a cysteine introduced near the active site of an AP to give a hybrid enzyme. The cysteine on the hybrid enzyme serves as a point of conjugation of a ligand, such as theophylline, ferritin, thyroxine, or digoxigenin, to form the hybrid enzyme-ligand conjugate. The ligand binds with an antibody, an analyte or a binding molecule to an analyte and as a result of this binding, the enzymatic activity of the hybrid enzyme-ligand conjugate is modified or modulated.

公开(公告)号：EP0734531A1

公开(公告)日：1996-10-02

申请号：EP95905393.0

申请日：1994-12-16

Applicant: Abbott Laboratories

Inventor： MARCH, Steven, C. ,  JENG, Tzyy-Wen

IPC: G01N33 ,  G06F19

CPC classification number: G01N33/743 ,  G06F19/00 ,  G16H40/63

Abstract: Provided is a highly reliable method to predict the beginning and/or ending of the fertile period for a female for each menstrual cycle. The methods and means provided advantageously address the day-to-day, cycle-to-cycle, and women-to-women variability in fertility hormone levels by analyzing the measurements of serial hormone concentrations in the midst of daily hormonal variations to determine when an actual and significant increase in the concentration of the monitored hormone has begun. Thus the present disclosure is directed to a method that combines existing hormone assay methods with calculation procedures to optimize the predictive values of daily hormonal changes. In this way a reliable and useful prediction of the fertile period is achieved with the concomitant assurance that the beginning and/or end of the fertile period has been reached so that such declarations are sufficient to provide both fertility enhancement and contraceptive utility.